Vitamin K2 and the “calcium traffic cop” idea: a strong mechanism still waiting on the outcomes

What vitamin K2 actually is (and how it differs from K1)

“Vitamin K” is not one molecule but a family, and the distinction matters more here than almost anywhere else in the supplement world. Vitamin K1 (phylloquinone) is the form in leafy greens — kale, spinach, broccoli — and it is the one your liver grabs first to run blood clotting. Vitamin K2 is a group of related compounds called menaquinones, produced by bacteria (including some in fermented foods and your own gut) and abbreviated MK-n, where n counts the length of the molecule’s side chain. The two that matter are MK-4 and MK-7.

The difference between MK-4 and MK-7 is not trivia — it changes how the supplement behaves. MK-7, the form concentrated in natto (fermented soybeans), has a long side chain that keeps it circulating in the blood for far longer: a single daily dose maintains steady levels, and it reaches tissues beyond the liver — including bone and artery wall — where its calcium-directing job actually happens. MK-4 has a much shorter half-life, clears within hours, and is the form used in Japan as a licensed osteoporosis drug — but at pharmaceutical doses of 45 mg per day, roughly 250 to 500 times a typical supplement.⁵ When a bottle says “K2 as MK-7,” that is the form with the bioavailability data behind the small daily doses most people take.

Here is the framing that makes K2 click: K1 is largely about clotting, while K2 is largely about steering calcium. They overlap, but the supplement conversation — bone, heart, arteries — is a K2 conversation. And that steering job runs entirely through one biochemical trick, which is where the story gets good.

The mechanism: the calcium traffic cop

This is the section where vitamin K2 earns its reputation, because the mechanism is not hand-waved — it is one of the cleaner stories in nutritional biochemistry.

Vitamin K’s single molecular job is to act as a cofactor for an enzyme that performs carboxylation — a chemical modification that switches certain proteins from an inactive form to an active one. Two of those proteins are the whole point here. Osteocalcin, made by bone-building cells, can only bind and lock calcium into the bone matrix after it has been carboxylated — and vitamin K is what carboxylates it. Matrix Gla protein (MGP), found in blood-vessel walls and cartilage, is the body’s most potent natural inhibitor of soft-tissue calcification — it actively keeps calcium out of arteries — and it, too, only works once vitamin K has carboxylated it.⁵

Put those together and you get the “calcium traffic cop” idea. When vitamin K is abundant, osteocalcin is switched on to pull calcium into bone, and MGP is switched on to keep calcium out of arterial walls. The signal K2 pulls is directional: not “more calcium” or “less calcium,” but calcium routed to where it belongs and away from where it does harm. When K2 is scarce, both proteins circulate in their inactive, uncarboxylated state — bone loses a tool for capturing mineral, and arteries lose a brake on calcifying. The blood level of uncarboxylated MGP (specifically, dephospho-uncarboxylated MGP, or dp-ucMGP) is now used as a marker of vitamin K status, and MK-7 supplementation reliably drives it down — that is, it activates more of the protein.²

This is why K2 is genuinely different from “take more calcium.” A calcium supplement adds mineral to the system; K2 governs where that mineral is deposited. It is a plausible, mechanistically elegant reason to care about K2 status — and the carboxylation effect itself is well enough established that we grade the biomarker claim MODERATE rather than the WEAK verdict most supplement mechanisms earn. The honest question, as always, is whether moving that surrogate marker translates into fewer fractures and fewer heart attacks. That is where we go next.

K2 does not add calcium to the system. It decides where the calcium you already have ends up — into bone, or into artery wall. The mechanism is beautiful. The outcome data are the part still being written.

The evidence: bone, arteries, and mortality

The evidence for K2 splits into three streams — bone, arteries, and cardiovascular mortality — and they are at genuinely different stages of maturity. Reading them as one blurred “K2 is good for you” is exactly the mistake the marketing wants you to make.

Bone. The biological case is strong — carboxylated osteocalcin captures calcium — and the Japanese experience with high-dose MK-4 (45 mg/day) as a licensed osteoporosis treatment lends real weight. For the low-dose MK-7 most people actually take, the best single trial is Knapen 2013: three years of 180 mcg MK-7 daily in 244 healthy postmenopausal women significantly improved carboxylated osteocalcin and slowed the age-related loss of bone mineral density at the spine and femoral neck versus placebo.³ That is a real, multi-year signal on a surrogate outcome. But when you zoom out to fractures — the outcome that matters — the picture gets murkier. The Cockayne 2006 meta-analysis found that most fracture benefit came from Japanese trials of high-dose MK-4, and concluded the fracture evidence outside that setting is far weaker and needs confirmation.⁶ So: good biomarker and bone-density data, a stronger MK-4 fracture signal that is partly geography-bound and debated, and thin Western fracture data. That is textbook EMERGING.

Arteries. The mechanistic hook here is MGP keeping calcium out of vessel walls, and the standout human trial is Knapen 2015: the same three-year, 180 mcg/day MK-7 protocol in healthy postmenopausal women significantly improved arterial stiffness (measured by carotid pulse-wave characteristics), with the largest benefit in women whose arteries were stiffest to begin with.² That is one of the more encouraging randomized results in the whole K2 literature — a hard-ish vascular surrogate moved over three years. The caveat is that arterial stiffness is still a surrogate, not a heart attack, and we do not yet have large trials showing MK-7 prevents cardiovascular events. Promising RCT, surrogate endpoint, no hard-outcome confirmation yet — again EMERGING.

Mortality and calcification (observational). The famous data come from the Dutch cohorts. The Rotterdam Study (Geleijnse 2004) followed roughly 4,800 adults and found that the highest tertile of dietary menaquinone (K2) intake was associated with markedly lower coronary heart disease mortality and less severe aortic calcification — while K1 intake showed no such link.¹ The Gast 2009 cohort of 16,057 women similarly found higher K2 intake associated with fewer coronary events, with the longer-chain menaquinones (MK-7 through MK-9) doing the work.⁴ And Beulens 2009 tied higher dietary K2 to less coronary calcification on imaging — the very outcome the MGP mechanism predicts.⁷ Three independent cohorts, one consistent direction, and a mechanism that explains it: that earns the mortality-association claim a MODERATE. But — and this is the load-bearing caveat — these are observational. People who eat more K2-rich food may differ in a hundred unmeasured ways. Association is not causation, and only a randomized hard-outcome trial can close that gap.

Line the streams up and the shape is clear. The carboxylation biomarker is nailed down. The bone-density and arterial-stiffness surrogates have real multi-year RCT support. The hard outcomes — fractures in Western populations, cardiovascular events — rest on observational data and high-dose MK-4 studies that do not cleanly transfer to a 180 mcg MK-7 capsule. Every honest grade on this page follows that gradient from proven mechanism to emerging outcome.

D3 + K2, dosing, and food sources

Rather than hand out a protocol — K2 has a genuine drug interaction and belongs in a clinician conversation for anyone on blood thinners — it is more useful to describe what the studies and the food supply actually contain, and the logic behind the popular pairings.

• Foundational (food first). The richest natural source of MK-7 by a wide margin is natto, the fermented-soybean dish; a single serving can supply several times a typical supplement dose. Beyond natto, K2 appears in smaller amounts in some aged and hard cheeses (Gouda, Edam, certain blues), egg yolk, and organ meats and dark poultry meat. Most Western diets are low in K2 specifically because natto is rare on the plate — which is the real argument for why a supplement might matter for people who never eat it.
• Research-curious (what trials used). The MK-7 trials behind the evidence above used roughly 90 to 180 mcg of MK-7 per day, taken as a single daily dose — the long half-life is what lets once-daily work.³ The Japanese osteoporosis data, by contrast, come from a completely different regimen: prescription-grade MK-4 at 45 mg/day, which is a licensed medicine, not a supplement, and should not be conflated with the small MK-7 doses on a store shelf. That describes what was studied — it is a description, not a personal prescription.
• Experimental / clinician-guided (the D3 pairing and edge cases). The popular D3 + K2 combination has a tidy rationale: vitamin D3 increases how much calcium you absorb from the gut, and K2 (via MGP and osteocalcin) governs where that extra calcium is deposited — so pairing them is meant to make sure D3’s added calcium lands in bone rather than artery. It is a plausible, physiologically coherent idea. It is also not proven to change fracture or cardiovascular outcomes in a randomized trial — the pairing is mechanism-led, not outcome-proven. Anyone on warfarin or other vitamin K antagonists, with a bleeding disorder, or on other anticoagulants belongs firmly in this tier: a clinician conversation, not a self-experiment.

The through-line: the closer you stay to the studied inputs — MK-7 in the 90–180 mcg range, or better yet natto on the plate, after clearing any blood-thinner interaction — the more the evidence above actually applies to you. Reach for 45 mg MK-4 or assume the D3 pairing prevents heart attacks, and you are extrapolating well past the data.

Grey areas: where the claims outrun the data

Two honest limitations keep K2 from being the miracle its marketing implies, and they deserve stating as plainly as the strong mechanism.

The first is the surrogate-to-outcome gap. Almost everything impressive about K2 is measured on a surrogate: carboxylation status, bone-mineral density, arterial stiffness, dp-ucMGP. Those are meaningful, mechanistically relevant markers — but the leap from “improves arterial stiffness over three years” to “prevents heart disease” is precisely the leap that has broken many a promising supplement. The hard-outcome cardiovascular RCT evidence for K2 is still emerging, and the specific consumer claim that K2 (especially with D3) “cleans out your arteries” or “reverses arterial calcification” runs well ahead of what any randomized trial has shown.² That is why that claim grades WEAK while the biomarker claim grades MODERATE — same molecule, very different strength of proof.

The second is the warfarin interaction, which is not a footnote but a genuine safety issue. Warfarin works by blocking vitamin K to thin the blood; supplementing vitamin K — K1 or K2 — directly opposes it and can push the INR out of its safe range, raising clotting risk. Anyone on warfarin or another vitamin K antagonist must not start K2 without their prescriber’s involvement.⁵ (Interestingly, MK-7’s long half-life may make it destabilize INR more than K1 at equivalent amounts — another reason the “it’s just a vitamin” framing is wrong here.) As a dietitian, I read K2 as a favourable but conditional bet: a mechanistically excellent, food-first nutrient with strong surrogate data and a real drug interaction, whose biggest problem is not danger but overstatement — being sold as a proven heart and bone cure when the outcome trials that would justify that are not yet in.

Open questions

Naming the gaps is the most useful thing this article can do, because they are specific and, in some cases, already being tested. First, the big one: do the surrogate wins become hard-outcome wins? We need large, long randomized trials powered for actual fractures and actual cardiovascular events — not just density and stiffness — before K2 graduates from “emerging” to “proven.”² Second, MK-4 versus MK-7 is unresolved: the fracture evidence leans on high-dose MK-4, the bioavailability and convenience favour MK-7, and whether low-dose MK-7 can match the MK-4 fracture signal is genuinely open.⁶ Third, the D3 + K2 pairing is assumed to be synergistic but has essentially no outcome-trial data of its own — the synergy is inferred from mechanism, not demonstrated. Fourth, who benefits most is unclear: people with low dietary K2 and high uncarboxylated-protein markers are the obvious candidates, but that hypothesis has not been cleanly tested. None of these gaps discredit the mechanism; they define exactly how far past it you can currently see.

The verdict

Vitamin K2 is the rare supplement whose mechanism is stronger than its outcome data — the opposite of most of the shelf. The carboxylation biology is real and well characterized: K2 activates osteocalcin to route calcium into bone and MGP to keep it out of arteries, and MK-7 reliably improves those markers.⁵ On surrogate outcomes it delivers — a three-year MK-7 trial slowed bone loss, another improved arterial stiffness, and three independent cohorts tie higher K2 intake to less arterial calcification and lower cardiac mortality.¹²³⁷ What it does not yet have is the hard-outcome randomized proof — fewer fractures, fewer heart attacks — that would move it from promising to established. That gap is why the honest grades run MODERATE for the biomarker and mortality-association claims, EMERGING for the bone and artery outcomes, and WEAK for the “prevents heart disease / cleans arteries” claim.

So who is it for? If you rarely or never eat natto, your dietary K2 is probably low, and a 90–180 mcg MK-7 supplement is one of the more defensible, low-risk bets on the shelf — mechanistically sound, cheap, and with genuine surrogate-marker support — provided you are not on warfarin or another vitamin K antagonist, in which case this is strictly a clinician conversation. Pair it with D3 if you like the logic, but hold the expectation at the right level: you are supporting the calcium-directing machinery your diet may be underfeeding, not buying proven protection from fractures or heart attacks. Judged as what it actually is — a strong-mechanism, good-surrogate, emerging-outcome nutrient that is genuinely useful for carboxylation status and oversold wherever the claims outrun the trials — vitamin K2 is worth understanding, worth eating for, and worth grading with exactly this much care.

K2 rarely acts alone in these protocols — it sits next to the fat-soluble and mineral levers it partners with. Our vitamin D mortality-curve and magnesium and vitamin D reads cover the D3 side of the pairing, while CoQ10 / ubiquinol, nattokinase (the other natto-derived compound), and calcium AKG round out the cardiovascular-and-aging shelf on the same honest scale.